Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e announcing the director changes discussed under Item 5.02 above. A copy of the press release is furnished as Exhibit 9 |
Stammdaten
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Unternehmen & Branche
| Name | Silence Therapeutics plc |
|---|---|
| Ticker | SLN |
| CIK | 0001479615 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 82686Q101 |
|---|---|
| ISIN | US82686Q1013 |
| Typ | ADR |
| Marktkapitalisierung | 367,7 Mio. USD |
| Beta | 1,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 559,000 | -88,612,000 | -0.63 | 131,442,000 | 62,304,000 |
| 2025-09-30 | 10-Q | 159,000 | -20,958,000 | -0.15 | 146,790,000 | 74,063,000 |
| 2025-06-30 | 10-Q | 224,000 | -27,354,000 | -0.19 | 165,233,000 | 94,155,000 |
| 2025-03-31 | 10-Q | 142,000 | -28,530,000 | -0.20 | 185,298,000 | 112,743,000 |
| 2024-12-31 | 10-K | 43,258,000 | -45,309,000 | -0.33 | 202,635,000 | 134,023,000 |
| 2024-09-30 | 10-Q | 1,498,000 | -35,544,000 | -0.25 | 126,696,000 | |
| 2024-06-30 | 10-Q | 756,000 | -19,755,000 | -0.14 | 142,527,000 | |
| 2024-03-31 | 10-Q | 15,699,000 | -2,312,000 | -0.02 | 156,762,000 | |
| 2023-12-31 | 10-K | 31,643,000 | -54,228,000 | -0.49 | 119,448,000 | 21,993,000 |
| 2022-12-31 | 10-K | 21,655,000 | -50,334,000 | -0.52 | 27,221,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Siren, L.L.C. | 2,911,438 | 0 | 2,911,438 | 17,701,543 | Neu | +100,0% | |
| Redmile Group, LLC | 2,164,777 | 0 | 2,164,777 | 13,161,844 | Neu | +100,0% | |
| Nantahala Capital Management, LLC | 1,542,427 | 0 | 1,542,427 | 9,377,956 | Neu | +100,0% | |
| Nextech Invest, Ltd. | 952,400 | 0 | 952,400 | 5,790,592 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 659,592 | 0 | 659,592 | 4,010,319 | Neu | +100,0% | |
| 5AM Venture Management, LLC | 476,200 | 0 | 476,200 | 2,895,296 | Neu | +100,0% | |
| MORGAN STANLEY | 324,630 | 0 | 324,630 | 1,973,750 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 258,861 | 0 | 258,861 | 1,573,875 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 209,088 | 0 | 209,088 | 1,271,255 | Neu | +100,0% | |
| UBS Group AG | 207,513 | 0 | 207,513 | 1,261,679 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 172,834 | 0 | 172,834 | 1,071,571 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 160,474 | 0 | 160,474 | 975,682 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 155,680 | 0 | 155,680 | 946,535 | Neu | +100,0% | |
| BlackRock, Inc. | 73,153 | 0 | 73,153 | 444,770 | Neu | +100,0% | |
| Quadrature Capital Ltd | 54,380 | 0 | 54,380 | 330,630 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 41,866 | 0 | 41,866 | 254,545 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 39,344 | 0 | 39,344 | 239,212 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 34,962 | 0 | 34,962 | 212,569 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 29,538 | 0 | 29,538 | 179,591 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 29,168 | 0 | 29,168 | 177,342 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 25,000 | 0 | 25,000 | 152,000 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 23,643 | 0 | 23,643 | 143,749 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 18,114 | 0 | 18,114 | 110,133 | Neu | +100,0% | |
| China Universal Asset Management Co., Ltd. | 13,653 | 0 | 13,653 | 83,010 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 12,999 | 0 | 12,999 | 79,027 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 12,027 | 0 | 12,027 | 73,124 | Neu | +100,0% | |
| XTX Topco Ltd | 11,718 | 0 | 11,718 | 71,245 | Neu | +100,0% | |
| GAMMA Investing LLC | 10,112 | 0 | 10,112 | 61,481 | Neu | +100,0% | |
| SIMPLEX TRADING, LLC | 9,991 | 0 | 9,991 | 60,745 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 7,942 | 0 | 7,942 | 48,287 | Neu | +100,0% | |
| BARCLAYS PLC | 5,065 | 0 | 5,065 | 30,795 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 2,966 | 0 | 2,966 | 18,033 | Neu | +100,0% | |
| JONES FINANCIAL COMPANIES LLLP | 2,500 | 0 | 2,500 | 15,200 | Neu | +100,0% | |
| Tower Research Capital LLC (TRC) | 2,448 | 0 | 2,448 | 14,884 | Neu | +100,0% | |
| CITIGROUP INC | 1,621 | 0 | 1,621 | 9,856 | Neu | +100,0% | |
| Parallel Advisors, LLC | 1,300 | 0 | 1,300 | 7,904 | Neu | +100,0% | |
| GF FUND MANAGEMENT CO. LTD. | 922 | 0 | 922 | 5,606 | Neu | +100,0% | |
| SG Americas Securities, LLC | 256,340 | 0 | 256,340 | 1,559 | Neu | +100,0% | |
| Steward Partners Investment Advisory, LLC | 100 | 0 | 100 | 608 | Neu | +100,0% | |
| Rockefeller Capital Management L.P. | 45 | 0 | 45 | 274 | Neu | +100,0% | |
| SBI Securities Co., Ltd. | 28 | 0 | 28 | 170 | Neu | +100,0% | |
| SageView Advisory Group, LLC | 11 | 0 | 11 | 67 | Neu | +100,0% | |
| OSAIC HOLDINGS, INC. | 3 | 0 | 3 | 18 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 16 | 0 | 16 | 0 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-25 | 1.059 | 5,20 | 5.507 |
| 2026-03-10 | 1.500 | 6,19 | 9.285 |
| 2026-03-06 | 34.316 | 5,50 | 188.738 |
| 2026-02-26 | 27.785 | 5,35 | 148.650 |
| 2026-02-25 | 27.921 | 5,33 | 148.819 |
| 2026-02-24 | 14.417 | 5,04 | 72.662 |
| 2026-02-23 | 6.666 | 5,00 | 33.330 |
| 2026-02-19 | 32 | 4,86 | 156 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Siren, L.L.C. | 2,911,438 | 17,701,543 | 27.30 |
| Redmile Group, LLC | 2,164,777 | 13,161,844 | 20.30 |
| Nantahala Capital Management, LLC | 1,542,427 | 9,377,956 | 14.46 |
| Nextech Invest, Ltd. | 952,400 | 5,790,592 | 8.93 |
| MILLENNIUM MANAGEMENT LLC | 659,592 | 4,010,319 | 6.19 |
| 5AM Venture Management, LLC | 476,200 | 2,895,296 | 4.47 |
| MORGAN STANLEY | 324,630 | 1,973,750 | 3.04 |
| CITADEL ADVISORS LLC | 258,861 | 1,573,875 | 2.43 |
| BOOTHBAY FUND MANAGEMENT, LLC | 209,088 | 1,271,255 | 1.96 |
| UBS Group AG | 207,513 | 1,261,679 | 1.95 |
| HSBC HOLDINGS PLC | 172,834 | 1,071,571 | 1.65 |
| BANK OF MONTREAL /CAN/ | 160,474 | 975,682 | 1.50 |
| MARSHALL WACE, LLP | 155,680 | 946,535 | 1.46 |
| BlackRock, Inc. | 73,153 | 444,770 | 0.69 |
| Quadrature Capital Ltd | 54,380 | 330,630 | 0.51 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 41,866 | 254,545 | 0.39 |
| TWO SIGMA INVESTMENTS, LP | 39,344 | 239,212 | 0.37 |
| Qube Research & Technologies Ltd | 34,962 | 212,569 | 0.33 |
| GEODE CAPITAL MANAGEMENT, LLC | 29,538 | 179,591 | 0.28 |
| JANE STREET GROUP, LLC | 29,168 | 177,342 | 0.27 |